健信超导闯上市：系许建益家族控股企业，频繁现金分红

Group 1 - The core viewpoint of the article is that Ningbo Jianxin Superconducting Technology Co., Ltd. has submitted its prospectus for an IPO on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking it as the third company to apply for listing in 2025 and the fourth in A-shares [1][3] - Jianxin Superconducting was established in December 2013, originally known as Ningbo Kaifang Nuclear Magnetic Technology Co., Ltd., and is located in Ningbo, Zhejiang Province. The company has a registered capital of approximately 126 million yuan [3][4] - The major shareholders of Jianxin Superconducting include Xu Jianyi, Zheng Jie, and Xu Jianfen, with Xu Jianyi holding 41.51% of the shares, making him the controlling shareholder and chairman of the company [4] Group 2 - Jianxin Superconducting primarily engages in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, with key products including superconducting magnets, permanent magnets, and gradient coils, which account for about 50% of the core component costs of MRI equipment [4] - The company's revenue for the years 2022, 2023, and 2024 was approximately 359 million yuan, 451 million yuan, and 425 million yuan, respectively, with net profits of approximately 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan [4] - The total assets of Jianxin Superconducting as of December 31 for the years 2022, 2023, and 2024 were 527.11 million yuan, 643.48 million yuan, and 671.28 million yuan, respectively, with a debt-to-asset ratio of 32.25%, 32.33%, and 29.48% [5] Group 3 - The company has a history of cash dividends, having declared a cash dividend of 10 million yuan in June 2022, followed by 19.99 million yuan in June 2023 and June 2024, and again 19.99 million yuan in March 2025 [6] - Jianxin Superconducting plans to raise 865 million yuan through its IPO, which will be used for projects including the annual production of 600 sets of liquid helium-free superconducting magnets, technical upgrades for high-field medical superconducting magnets, and new superconducting magnet research and development [8]